Charleston Laboratories, Inc. Announces Publication of Abstract for CL-108 Phase 3 Study at APS 2014

Jupiter, Florida – May 2, 2014 – Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the publication of an abstract and presentation of a poster entitled, “Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting,” at the 2014 Annual Meeting of the American Pain Society being held in Tampa, Florida this week. The poster will be author attended on Friday May 2nd from 8:45am to 10:15am by Dr. Bernard Schachtel, Chief Scientific Officer of Charleston Laboratories.

This abstract was published in the April 2014 issue of the Journal of Pain, the official journal of the American Pain Society.